Clearance of psoriasis: 31.25% (IA), 33.3% (IB), and 76.7% (II). PASI scores were reduced within each group. The UVA group achieved results comparable to PUVA until session 24 but failed to match it at the final evaluation. Both treatments caused a reduction in dermal lymphocytic counts and epidermal bcl-2 expression. The gene discussed is BCL2; the disease is psoriasis.